Ras is one of the most frequently activated oncogenes in cancer. Two mitogen-activated protein kinases (MAPKs) are important for ras transformation: extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase 2 (JNK2). Here we present a downstream signal amplification cascade that is critical for ras transformation in murine embryonic fibroblasts. This cascade is coordinated by ERK and JNK2 MAPKs, whose Rasmediated activation leads to the enhanced levels of three oncogenic transcription factors, namely, c-Myc, activating transcription factor 2 (ATF2) and ATF3, all of which are essential for ras transformation. Previous studies show that ERK-mediated serine 62 phosphorylation protects c-Myc from proteasomal degradation. ERK is, however, not alone sufficient to stabilize c-Myc but requires the cooperation of cancerous inhibitor of protein phosphatase 2A (CIP2A), an oncogene that counteracts protein phosphatase 2A-mediated dephosphorylation of c-Myc. Here we show that JNK2 regulates Cip2a transcription via ATF2. ATF2 and c-Myc cooperate to activate the transcription of ATF3. Remarkably, not only ectopic JNK2, but also ectopic ATF2, CIP2A, c-Myc and ATF3 are sufficient to rescue the defective ras transformation of JNK2-deficient cells. Thus, these data identify the key signal converging point of JNK2 and ERK pathways and underline the central role of CIP2A in ras transformation.
Introduction
Activating mutations in ras are found in close to 30% of human cancers. Among the most central downstream kinases of Ras are the mitogen-activated protein kinase (MAPK) family members c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK). Studies with immortalized mouse embryonic fibroblasts (MEFs) have indicated that both ERK and JNK activation is necessary for ras transformation. The central contribution of the ERK pathway in transformation is shown by the ability of the constitutively active mutants of ERK and its upstream kinase Raf to transform NIH3T3 MEFs (Cowley et al., 1994; Mansour et al., 1994; Khosravi-Far et al., 1996) and by the capability of the corresponding dominant-negative mutants and inhibitors of ERK upstream kinase MEK to inhibit ras transformation and growth of both MEFs and human cancer cells (Kolch et al., 1991; Troppmair et al., 1994) . Interestingly, the JNK isoforms JNK1 and JNK2 have differing roles in ras transformation. The JNK2 isoform of JNK, but not JNK1, is necessary for ras transformation of MEFs (Nielsen et al., 2007) . The Jnk2À/À cells have severely reduced capacity for ras transformation both in vitro and in vivo. Despite being deficient in ras transformation, these cells exhibit strong Ras-mediated c-Jun accumulation and activation (Nielsen et al., 2007) . In vivo support for the role of JNK2 in ras transformation comes from the 7,12-dimethylbenz(a)anthracene/12-O-tetradecanoyl-phorbol-13-acetate-induced murine skin tumorigenesis model, which induces Ras activation in the skin (Kemp, 2005) , leading to decreased tumor burden in Jnk2-null mice in comparison with corresponding Jnk1-deficient or wild-type mice (Chen et al., 2001) . JNK2 is also essential for ras transformation of human epithelial cells (Ke et al., 2010) . Despite accumulating data showing the importance of both ERK and JNK in ras transformation, the downstream signaling events and mechanisms explaining how these two different MAPK pathways cooperate and support ras transformation are not known.
The majority of the known MAPK targets are transcription factors. Activator protein 1 (AP-1) and c-Myc transcription factors are both targets of MAPK activation, and have been intensively studied because of their central role in transformation and cancer. The AP-1 component c-Jun, which is an oncogene itself and the best characterised JNK substrate, is phosphorylated by Ras-induced signaling and essential for ras transformation Smeal et al., 1991; Johnson et al., 1996; Behrens et al., 2000) . JNK facilitates c-Jun activity by phosphorylating serine (Ser) 63 and 73 in its activation domain (Hibi et al., 1993; Derijard et al., 1994; Kyriakis et al., 1994) . The fact that c-Jun Ala-Ala knock-in mice, in which c-Jun Ser 63 and 73 are replaced with alanines, retained partial transformation capacity (Behrens et al., 2000) , suggests that additional JNK targets other than c-Jun may be involved in cellular transformation by ras. The activating transcription factor 2 (ATF2) is another oncogenic target that can be activated by JNK, but also by MAPK p38, on phosphorylation of its Thr 69 and 71 Livingstone et al., 1995; Raingeaud et al., 1995) . ATF2 belongs to the ATF family of transcription factors that shares the basic-region leucine-zipper element but is otherwise very heterogeneous. ATF2 protein level is regulated by proteosomal degradation, which can be blocked by JNK-mediated phosphorylation of ATF2 at Thr 69 and 71 (Fuchs et al., 2000) . ATF2 forms homodimers and heterodimers with the c-Jun family members, regulating the AP-1 transcription factor activity and DNA binding specificity. In addition to being an oncogene, ATF2 can also function as a tumor suppressor, and the properties of ATF2 that support and mediate these two different functions are poorly characterized (Bhoumik and Ronai, 2008) .
The transcription factor c-Myc is a key regulator of the cell cycle and enhanced c-myc expression can result in tumorigenesis. Some of the established functions of c-Myc in regulation of cell cycle progression are repression of p21Cip1 and induction of cyclin D gene transcription (Eilers and Eisenman, 2008) . Furthermore, c-Myc is shown to assist oncogenic Ras in transformation and overexpression of oncogenic Ras results in c-Myc accumulation (Land et al., 1986; Sears et al., 1999) . c-Myc is tightly regulated at the transcriptional and post-translational level. Phosphorylation of c-Myc induced by ERK and/or JNK on c-Myc Ser 62 protects c-Myc from proteasomal degradation (Sears et al., 1999 (Sears et al., , 2000 Alarcon-Vargas and Ronai, 2004) . This site is actively dephosphorylated by protein phosphatase 2A (PP2A) in non-cancerous cells, but on oncogenic stimulation becomes protected by cancerous inhibitor of PP2A (CIP2A), whose expression thereby stabilizes c-Myc (Junttila et al., 2007; Come et al., 2009; Khanna et al., 2009) . How oncogenic activation increases CIP2A levels over the threshold that is needed for the stabilization of c-Myc is still poorly understood.
To study how JNK signaling contributes to ras transformation, we used immortalized Jnk2À/À MEFs with severely reduced ras transformation capacity (Nielsen et al., 2007) . For this, we investigated the phosphorylation status of the two highly oncogenic JNK substrates, ATF2 and c-Myc, and found that both ATF2 and c-Myc protein levels were low in Jnk2À/À MEFs. Both protein and mRNA levels of CIP2A in Jnk2À/À MEFs in comparison with Jnk1À/À or wild-type (wt) MEFs were low. With RNA interference, quantitative real-time PCR (qPCR), chromatin immunoprecipitation (ChIP) and overexpression studies, we identified a Ras-activated positive transformation promoting signaling cascade involving JNK2, ERK, CIP2A, c-Myc and ATF2. It begins by Ras activating JNK2 and ERK, and leads to increased levels of CIP2A, c-Myc and ATF2. With expression array analysis, ChIP, qPCR and luciferase reporter analysis we identified Atf3 as one important downstream target gene of c-Myc and ATF2 in ras-mediated cellular transformation.
Results
Ras-mediated constitutive ERK activation is not sufficient to transform Jnk2À/À MEFs Mammalian Ras is expressed by three genes as four isoforms; KA-, KB-, N-and H-Ras. Most human cancers expressing activated Ras have prevalence for mutation of one particular isoform of ras. However, so far no transformation-related functional differences have been established for these different Ras isoforms, which all are capable of transforming cells both in vitro and in vivo (Malumbres and Barbacid, 2003) . The JNK2 isoform of JNK is necessary for H-ras transformation of MEFs (Nielsen et al., 2007) . To investigate if this is true for all ras isoforms, immortalized wt and JNK2-knockout (Jnk2À/À) MEFs were retrovirally infected with each of the constitutively active ras isoforms, H-ras, N-ras and K-ras, and analyzed for multilayered focus formation, choosing the KA isoform to represent K-ras, as it is the form present in the transforming retrovirus carrying the K-ras gene. As JNK3 is not expressed in MEFs, the Jnk2À/À MEFs express only one JNK isoform; JNK1 (Tournier et al., 2000; Nielsen et al., 2007) . Immortalized Jnk2À/À MEFs expressing any of the Ras isoforms had severely impaired capability to form multilayer foci compared with corresponding wt MEFs ( Figure 1a ). All three ectopically expressed Ras isoforms tested were well expressed in Jnk2À/À MEFs (Figure 1b) . The expression of both endogenous N-ras and K-ras was slightly increased in control vector expressing Jnk2À/À cells in comparison with the corresponding wt cells (Figure 1b) , which however was not sufficient to transform them. As none of the Ras isoforms transformed Jnk2À/À MEFs, we continued to use H-Ras as a representative of the Ras family, which will from now on be referred to as Ras. Importantly, a constitutively active form of the Ras downstream effector MEK1, that transforms NIH3T3 cells (Brunet et al., 1994) , was found to transform immortalized wt and Jnk1À/À MEFs but was not capable of transforming corresponding Jnk2À/À MEFs (Supplementary Figure 1a) , even though ERK was strongly activated by Ras in immortalized Jnk2À/À MEFs, which was detected as increased ERK phosphorylation (Figure 1c ). Some ERK activation was also detected in Jnk2À/À MEFs expressing control vector (À), which was probably due to increased expression of endogenous N-and K-Ras (Figure 1b ). Consequent to ERK activation, several ERK substrates were phosphorylated, indicating that ERK was fully functional in Jnk2À/À MEFs (Supplementary Figure 1b) . As expected, re-introduction of JNK2 into primary Jnk2À/À MEFs followed by immortalization with the 3T3 method rescued the transformation defect of the Jnk2À/À cells on Ras transduction (Figure 1d, Supplementary Figure 1c) . Altogether these data show that in the absence of JNK2, MEFs cannot be transformed with oncogenic Ras even though their ERK signaling is efficiently activated.
c-Myc, ATF2 and CIP2A are downregulated in Jnk2À/À MEFs The Ras-induced phosphorylation of Ser 63 and 73 in c-Jun is intact in Jnk2À/À MEFs and no defect in the AP-1 activity is observed when measuring the c-Jun luciferase reporter construct (Nielsen et al., 2007) . Thus, we turned our focus to other JNK substrates with oncogenic potential. We found that Jnk2À/À MEFs had severely reduced phosphorylation of ATF2 at the JNK phosphorylation sites Thr 69 and 71, and that the ectopic expression of active Ras was not able to increase it. The reduced phosphorylation coincided with a decreased ATF2 protein level (Figure 2a) , which was most likely due to the lack of JNK-mediated ATF2 stabilizing phosphorylation of Thr 69 and 71 Fuchs et al., 2000) . We showed earlier that ectopic expression of c-myc oncogene could rescue the impaired Ras transformation of the Jnk2À/À MEFs (Nielsen et al., 2007) . Because both ERK and JNK can phosphorylate Ser 62 in c-Myc and thus increase c-Myc stability (Noguchi et al., 1999) , we investigated c-Myc phosphorylation and found it to be lower in Jnk2À/À cells than in wt cells (Figure 2a) . Consequently, also the c-Myc levels were down in the Jnk2À/À þ Ras MEFs ( Figure 2a ). As CIP2A can stabilize c-Myc, and we found CIP2A to rescue the Ras transformation defect of Jnk2À/À cells (Figure 2b ), we also studied the CIP2A level and found it to be low in Jnk2À/À cells ( Figure 2a ). In addition to CIP2A, introduction of ATF2 or c-Myc into Jnk2À/À þ Ras cells rescued their Figure 3) . This data shows that in Ras-expressing MEFs, the c-Myc, ATF2 and CIP2A protein levels are dependent of JNK2, and that the ectopic expression of any of them rescues the transformation defect.
ATF2 regulates Cip2a expression in Jnk2À/À MEFs-ATF2, c-Myc and CIP2A are less stable in immortalized Jnk2À/À MEFs than in corresponding wt MEFs As ectopic expression of ATF2, c-Myc or CIP2A rescued the Ras transformation defect of the Jnk2À/À cells (Figure 2b ), we next investigated the mRNA levels of Atf2, c-myc and Cip2a (KIAA1524) in wt and Jnk2À/À MEFs. We found that the ATF2 mRNA level in Jnk2À/À þ Ras cells was very similar to its level in wt þ Ras cells ( Figure 3a) . Instead, c-myc mRNA level was induced by Ras in both cell lines, although the c-myc mRNA level in Jnk2À/À þ Ras MEFs was a bit lower than in the wt cells ( Figure 3a) . The Cip2a mRNA level was also down in Jnk2À/À þ Ras cells in comparison with wt þ Ras cells ( Figure 3a ). Ectopic expression of ATF2 in Jnk2À/À þ Ras MEFs restored the Cip2a mRNA to its level in wt þ Ras MEFs (Figure 3b ), suggesting that ATF2 may control the expression of Cip2a. Ectopic expression of ATF2 in Jnk2À/À þ Ras MEFs increased the level of the mRNA of c-myc, but was not sufficient to induce it to its level in the wt þ Ras (Figure 3b ). Supporting the Cip2a mRNA studies in Figure 3b , ChIP assay revealed that ATF2 bound in vivo to an AP-1 site in the proximal Cip2a promoter region between base pair 1250 and 1100 (region amplified) in wt MEFs, but about 70% less efficiently in Jnk2À/À MEFs (Figure 3c ). In addition to CIP2A, both c-Myc and ATF2 protein levels were approximately 60-70% lower in Jnk2À/À þ Ras MEFs ( Figure 2a ). As low ATF2 protein level could not be explained by its mRNA levels (Figure 3a) , we investigated the degradation of ATF2 following cycloheximide treatments to find out whether its stability was compromised in Jnk2À/À MEFs. When protein synthesis was blocked with cycloheximide, the turnover of ATF2 was clearly faster in Jnk2À/À MEFs than in wt MEFs, and so was that of c-Myc and CIP2A (Figure 3d ). Ectopic expression of ATF2 in Jnk2À/À þ Ras MEFs decreased the turnover of c-Myc and CIP2A to that in the wt cells (Figure 3d ). Altogether, these data suggest that JNK2 regulates c-Myc levels via ATF2-mediated Cip2a expression. In addition, it indicates that JNK2 is needed for the stability of these three proteins.
Atf3 is an important target of ATF2 and c-Myc in Ras-transformed MEFs While studying the MAPK signaling in MEFs, we also investigated gene expression differences between ATF2 and c-Myc co-operation in Ras transformation DP Mathiasen et al immortalized Jnk2À/À þ Ras and wt þ Ras using the Illumina's Sentrix Mouse (Ambion, Austin, TX, USA) expression array that contains most of the mouse genome. It did not however contain Cip2a. Overall the expression of many genes was altered, but their magnitude differences were very modest (unpublished data). We collected the known c-Myc targets from the array and found 12 of them to exhibit at least twofold higher expression in wt þ Ras compared with Jnk2À/À þ Ras (Table 1) . For further analysis, we chose Atf3, which is a known oncogene and a transcriptional target of both c-Myc and ATF2 in serum response (Tamura et al., 2005) . With qPCR, we verified the mRNA level of Atf3 to be lower in the Jnk2À/À þ Ras cells compared with wt þ Ras cells (Figure 4a ). Interestingly, introduction of either ATF2, c-Myc or CIP2A into Jnk2À/À þ Ras MEFs increased the Atf3 mRNA level to its level in the wt cells or more (Figure 4a ). The proximal Atf3 promoter region of Mus musculus has several AP-1 and cyclic AMP response element (CRE)-like motifs. We did ChIP analysis of the Atf3 promoter, and found most of the amplified fragments containing these elements to bind both ATF2 and c-Myc in a JNK2-dependent manner in vivo (Figure 4b ). We measured the activity of the human ATF3 reporter construct pLuc1850 that contains a functional ATF2-binding CRE-element (Cai et al., 2000) identical to the murine CRE-element M5, and found it to be clearly less active in Jnk2À/À þ Ras cells than in same cells expressing CIP2A (Figure 4c) . Similarly, its mutated version pLuc1850 m, which due to a point mutation in its CRE-element cannot bind ATF2 (Cai et al., 2000) , was clearly less active than the wt reporter in both cell lines (Figure 4c ). Introduction of ATF3 into Jnk2À/À þ Ras cells rescued their transformation defect ( Figure 5a ). Consequently, depletion of ATF3 from wt þ Ras cells made them deficient in Ras transformation ( Figure 5b ). Finally, introduction of CIP2A or ATF3 into Jnk2À/À þ Ras MEFs restored their transformation deficiency in vivo, and resulted in tumor growth similar to that of wt þ Ras MEFs in nude mice (Figure 5c ). This data altogether suggests that Atf3 is one of the key targets of Ras that are required for its transforming activity.
Discussion
We have identified a novel signal amplification mechanism and a converge point between JNK and ERK MAPK signaling pathways, on which they conjointly support Ras-mediated cellular transformation. We have identified a transformation mechanism involving JNK2 and ERK, whereby Ras-activated JNK2 stabilizes ATF2. ATF2 binds to the AP-1-transcription-factor binding site in the Cip2a promoter and facilitates its transcription. Meanwhile, Ras-activated ERK phosphorylates c-Myc on Ser 62. Accumulating CIP2A protects c-Myc Ser 62 from dephosphorylation by PP2A, and thus stabilizes c-Myc (Figure 6 ). This work gives novel mechanistic insight of how and where JNK and ERK signaling converges to support Ras transformation. Overexpression and activation of ATF2 is important for the tumor progression in melanoma in which the nuclear localization of active ATF2 has been associated with poor prognosis (Berger et al., 2003) . Furthermore, melanoma growth and metastasis can be inhibited with an ATF2-derived peptide (containing amino acids ATF2 and c-Myc co-operation in Ras transformation DP Mathiasen et al 51-100) that sequesters ATF2 into the cytoplasm, and thus inhibits its transcriptional activity (Bhoumik et al., 2004) . Our work suggests that sufficient accumulation of ATF2 is essential for the ability of Ras to induce transformation. We propose here that in Ras transformation, ATF2 regulates c-Myc stability by regulating Cip2a expression. Although the Atf2 mRNA level in Jnk2À/À þ Ras is comparable with that of the wt þ Ras, the ATF2 protein level in Jnk2À/À MEFs is too low to mediate the transcriptional changes induced by active Ras that are required to elicit a full transformed state, which includes increase in the level of CIP2A. JNK and p38 can both phosphorylate ATF2, although JNK has been suggested to be the primary kinase for ATF2 Thr 69 and 71 in MEFs Livingstone et al., 1995; Raingeaud et al., 1995) . In MEFs, the presence of both JNK1 and p38 is not enough to stabilize ATF2, which requires JNK2, and thus can be obtained by ectopic JNK2. The inability of Ras-activated JNK1 and p38 to sufficiently phosphorylate and stabilize ATF2 suggests refined substrate specificity among these MAPKs and their isoforms, as has previously been shown for JNK2 in comparison with JNK1 (Kallunki et al., 1994; Gupta et al., 1996) . Supportively, several studies show that JNK2 is indeed more cancer promoting than other JNK isoforms also in human epithelial cells (Bost et al., 1999; Potapova et al., 2000) and in different human cancers harboring Ras activation (Ke et al., 2010; Sharma et al., 2010) . The oncogenic properties of c-Myc are tightly associated with the complex regulation of its stability. c-Myc stabilization is enhanced in numerous cancers, and ERK is considered to stabilize c-Myc via phosphorylation of Ser 62 (Sears et al., 1999 (Sears et al., , 2000 . In vitro experiments have shown that JNK can phosphorylate the same site and could theoretically stabilize the c-Myc protein (Alarcon-Vargas and Ronai, 2004) . In the most common model for the mechanism of the transcriptional function of c-Myc, c-Myc binds to E-box sequences in the promoter region of its target genes and facilitates the transcription of these genes (Amati et al., 2001 ). Here we show that Atf3 is a target of both c-Myc and ATF2 in Ras transformation. We demonstrate that c-Myc binds (c) Luciferase reporter assay of ATF3 promoter construct (pLuc-1850) and a corresponding construct with the M1 site mutated so that it cannot bind ATF2 (pLuc-1850m). Indicated cells were transfected with firefly luciferase constructs of pLuc-1850 and pLuc-1850m together with renilla luciferase that was used to control the transfection efficiency. For the relative luciferase activity, the firefly luciferase activities were normalized to the corresponding renilla luciferase activities.
ATF2 and c-Myc co-operation in Ras transformation
DP Mathiasen et al to the Atf3 promoter at sites that do not contain an E-box. This supports a recent model whereby c-Myc identifies transcriptionally engaged genes and associates with specifically modified chromatin (Guccione et al., 2006) . Indeed, c-Myc actively regulates acetylation of multiple lysine sites of histones H3 and H4 (Martinato et al., 2008) , with a mechanism which is not fully understood. Interestingly, ATF2 possesses histone acetyltransferase activity (Kawasaki et al., 2000) , and could therefore be an ideal cooperation partner for c-Myc. Accordingly, some promoter regions, such as that of ATF3, could recruit c-Myc via ATF2 transcription factor complexes. This could allow c-Myc in cooperation with ATF2 to regulate transcription of such genes as ATF3 that are important for Rasmediated transformation but do not contain E-boxes. Identification of Atf3 as a Ras transformationsupporting gene is in line with its known oncogenic function that involves its ability to transform chick embryo fibroblasts (Perez et al., 2001) . Moreover, overexpression of ATF3 leads to mammary tumor formation in mice (Wang et al., 2008) . ATF3 is also expressed at high levels in a subset of human breast tumors indicating its oncogenic role (Wang et al., 2008 ).
Here we have described a novel Ras transformation promoting signaling cascade in mammalian cells that ATF2 and c-Myc co-operation in Ras transformation DP Mathiasen et al links MAP kinases ERK and JNK2 as well as the transcription factors c-Jun, ATF2, c-Myc and the PP2A inhibitor CIP2A that stabilizes c-Myc. We show that efficient cooperation of all of these components is necessary for Ras transformation. We demonstrate that Ras transformation depends on the Ras-mediated increased levels of both ATF2 and c-Myc transcription factors, which are transcriptionally (c-Myc) and post-translationally (ATF2 and c-Myc) regulated by JNK2 and ERK, respectively. We identify Cip2a as an important transcriptional target of ATF2 in Ras transformation. We also identify Atf3 as a transcriptional target of both c-Myc and ATF2, whose increased expression facilitates Ras transformation both in vitro and in vivo. Finally, our results suggest that specific targeting of JNK2 might be a useful strategy for therapy in cancers relying on high ATF2 and c-Myc activity.
Materials and methods
Antibodies H-Ras antibody is from hybridoma 146-3E4, the NCI Repository at Quality Biotech, Camden, NJ, USA; N-and K-Ras (Y13-259; Furth et al., 1982) and p-c-Myc (Ser 62) was from Bio-Academia (Osaka, Japan). P-c-Jun ( 
Plasmids
The viral H-Ras (Nielsen et al., 2007) , N-Ras and K-Ras have been described elsewhere (Nielsen et al., 2001) . ATF2 was cloned into pBabe (pB)-Neo at BamHI-SalI site. ATF3-pB is from T Hai (Yin et al., 2008) . The pLuc-1850 and pLuc1850m is from S Kitajima (Cai et al., 2000) . c-Myc and CIP2A pB puro (Junttila et al., 2007) and JNK2 pB puro (Dietrich et al., 2004) constructs are described in co-publications. For the ATF2 and c-Myc short hairpin constructs the corresponding primers ATF2 (forward: 5 0 -GATCCCCCAATGGTGATAC TGTAAAATTCAAGAGATTTTACAGTATCACCATTGTT TTTGGAAA-3 0 and reverse: 5 0 -AGCTTTTCCAAAAACA ATGGTGATACTGTAAAATCTCTTGAATTTTACAGTAT CACCATTGGGG-3 0 ) and c-Myc (forward: 5 0 -GATCCCCA GGTAGTGATCCTCAAAAATTCAAGAGATTTTTGAGG ATCACTACCTTTTTTGGAAA-3 0 and reverse: 5 0 -AGCTT TTCCAAAAAAGGTAGTGATCCTCAAAAATCTCTTGA ATTTTTGAGGATCACTACCTGGG-3 0 ) were cloned into pRetro-puro vector as described elsewhere (Nielsen et al., 2007) . Lentiviral ATF3 shRNA constructs TRCN0000082131 (ATF3-1), TRCN0000082132 (ATF3-2) and their control constructs SHC001 (empty vector) and SHC002 (N.T.R.CTR shRNA) were from Sigma-Aldrich The RNAi Consortium shRNA collection (St Louis, MO, USA; Functional Genomics Partnership Program).
Cell culture, retroviral and lentiviral gene transfer Embryos were harvested, and MEFs were established and immortalized as previously described (Nielsen et al., 2007) . The PhoenixEco packaging cells (G. Nolan Laboratory, Stanford University School of Medicine, Stanford, CA, USA), HEK 239, NIH3T3 fibroblasts and immortalized MEFs were cultured in Dulbecco's modied Eagle's medium supplemented with 10% fetal calf serum, 100 mg/ml of streptomycin and 100 U/ml penicillin. The retroviral gene transfer was carried out as described previously (Dietrich et al., 2004) . In cycloheximide experiments, cells were treated with cycloheximide (Sigma-Aldrich) at 365 pM for the indicated period of time in complete media. Lentiviral ATF3 shRNA constructs and control shRNA constructs were transfected into HEK-293 cells with packaging mix plasmids (Sigma-Aldrich). Supernatants of expressed pseudoviruses were harvested at 48 h after transfection, centrifuged and concentrated with Lentiviral Vector PEG-it Precipitation solution (System Biosciences, Mountain View, CA, USA). Immortalized wt þ Ras MEFs were infected for 24 h with viral supernatant at multiplicity of infection 10 000. Clones were verified for ATF3 gene suppression after 7 days with immunoblotting and set up for foci assays.
In vitro tumorigenicity assay Focus formation assay was carried out as described previously, and NIH3T3 fibroblasts were used as background cells for focus formation assay (Jacobsen et al., 2002; Nielsen et al., 2007) .
In vivo tumorigenicity assay The in vivo tumorigenicity experiment was carried out as described in Nielsen et al. (2007) . Figure 6 Schematic representation of the Ras-activated, transformation-promoting signal amplification loop involving JNK2, ERK, CIP2A, c-Myc and ATF2. To begin with, Ras activates MAP kinases JNK2 and ERK. Activated JNK2 phosphorylates threonines 69 and 71 in ATF2 and activated ERK phosphorylates serine 62 in c-Myc. On phosphorylation, these transcription factors become stabilized and start to accumulate. ATF2 binds to an AP-1-binding site in the proximal Cip2a promoter and facilitates its transcription. Increased CIP2A levels lead to the further accumulation of c-Myc, by protecting it from PP2A-mediated dephosphorylation and subsequent degradation. Increase in the level of CIP2A leads to increase in the c-Myc level, which together with ATF2 stimulates the transcription of Atf3, mediating Ras transformation. Jnk2-null cells most likely cannot be transformed by Ras because their ATF2 level is so low that it cannot support the expression of Cip2a. As a result, the basal level of c-Myc remains low, as the Ras-induced ERK-mediated phosphorylation of Ser 62 in c-Myc is not alone sufficient for its stabilization.
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Immunoblot analysis
The cells were lysed in TR3 lysis buffer (SDS 3%, glycerol 10%, Na 2 HPO 4 10 mM) and protein concentration was measured spectrophotometrically at 280 nm (NanoDrop, Thermo Fisher Scientific, Pittsburgh, PA, USA). Cell lysates were sonicated for 10 s before SDS-polyacrylamide gel electrophoresis separation and the immunoblots were prepared as described before (Dietrich et al., 2004 0 -GAGCTAGAAAACGCCCTG-3 0 and 5 0 -GAGGTTTCCC CGAATACTC-3 0 for porphobilinogen deaminase at 130 nM. PCR was initiated with a Taq activation step performed at 95 1C for 10 min followed by 45 amplification cycles of a 95 1C denaturation step for 1 s, 60 1C annealing step for 5 s and a 72 1C elongation step for 10 s. Data values were subjected to an absolute quantification analysis according to the manufacturer's guidelines. The expression in each sample was normalized to an external standard curve and evaluated relative to the porphobilinogen deaminase expression.
Expression array and data analysis Wt, Jnk1À/À and Jnk2À/À MEFs were retrovirally infected with pB-Puro or H-Ras pB-Puro and cells were harvested at 72 h after start of the infection. Total RNA (300 ng) was used for biotinylated complementary RNA synthesis (Ambion's Illumina RNA TotalPrep Amplification kit, Ambion, Austin, TX, USA). Samples were prepared as duplicates from two identical but independent infections. A total of 1.50 mg of each sample was hybridized to Illumina's Sentrix Mouse-6 Expression BeadChip, version 1.1 (cat. no. BD-26-103) at 58 1C according to Illumina WholeGenome Gene Expression with IntelliHyb protocol. Hybridization was detected with 1 mg/ml Cyanine3-streptavidin (GE Healthcare, Waukesha, WI, USA). Chips were scanned with Illumina BeadArray Reader and the raw data were extracted with Bead Studio v3.0 (Illumina, San Diego, CA, USA). The gene microarray data analysis was carried out with the Anduril framework (Ovaska et al., 2010) . The expression values were normalized using quantile normalization and the Illumina probe identifiers were annotated with the Ensembl mouse gene identifiers (v. 57; Hubbard et al., 2009 ; EMBL-EBI and Wellcome Trust Sanger Institute, Hinxton, UK). Fold changes were calculated for Jnk2À/À versus wt, and two replicates were combined by taking the mean of their fold changes. The list of the candidate genes was generated by taking only genes that are reported as targets in the Myc Target Gene Database (Zeller et al., 2003;  http://www.myc-cancer-gene.org/. First, the reported Myc targets in human, mouse, rat, chicken and drosophila were mapped to the homologous mouse Ensembl gene identifiers. Second, the genes from the expression data were filtered based on the list containing mouse genes homologous to Myc targets.
Chromatin immunoprecipitation
ChIP analysis was performed as described in the X-ChIP guidelines (Abcam, Cambridge, UK) from both Ras-transduced wt and Jnk2À/À MEFs. Sonication of whole-cell formaldehyde cross-linked lysate was performed with Bioruptor (Diagenode, Liege, Belgium) to produce DNA fragments with the size of 100-300 bp. Samples were immunoprecipitated and isolated DNA was amplified. Primer pair CIP2A #3 reverse: 5 0 -ATC GGGGGTAATGATGTGCACGGATCT-0 3 and CIP2A #3 forward: 5 0 -GTCAAATGGGCATTTACTCGATCCCACA-0 3 was used to amplify the AP-1 site in the proximal Cip2a promoter region. Following primer pairs were used to amplify indicated motif (M1-M5) containing sites in Atf3 proximal promoter region: M1 (ATF3 #7 reverse: 5 0 -GCAGTGAACCCT GACAGTTAAAGGGA-3 0 and ATF3 #7 forward: 5 0 -ACCGG CCACAGAAGAGCCTGA-3 0 ), M2 (ATF3 #4 reverse: 5 0 -CCT TGAGCTTTGCAGCCAGCG-3 0 and ATF3 #4 forward: 5 0 GG CTGTGAGTTCTGAAACCACGCAA-0 3), M3 (ATF3 #3 reverse: 5 0 CCTGGTCCCTCCACCCGCTT-3 0 and ATF3 #3 forward: 5 0 -GGGGCTGAAGGCCGAGAGGT-3 0 ), M4 (ATF3 #14 reverse: 5 0 -CCGGGAGCAGCGCTTCAACA-3 0 and ATF3 #14F: 5 0 -AGGGACGGAGGAGTTGCGCT-3 0 ), M5 (ATF3 #2 reverse: 5 0 -GAGCGCGTTGCATCACCCCT-3 0 and ATF3 #2 forward: 5 0 -GTGACCGCCCCTTCTCGCAC-3 0 ). Amplification was carried out with the Lightcycler (Roche) as described for the qPCR. Hemagglutinin antibody was used in negative control mmunoprecipitated, and values obtained from the negative control were subtracted from ATF2 ChIP and c-Myc ChIP. The data was presented as % of the input.
Luciferase reporter assay
The cells were transfected for 48 h with 1.5 mg of each firefly luciferase reporter construct together with 0.5 mg of pGL3 basic null-vector transcribing the Renilla luciferase gene. Luciferase assays were performed according to Dualluciferase reporter assay system (Promega, Madison, WI, USA). Luminescence was measured on an Enspire Multilabel Platereader (Perkin Elmer, Waltham, MA, USA). Firefly luciferase activities were normalized to renilla luciferase activity.
